CoChat
Sign Up
Cited by 272Lipoproteins and Cardiovascular HealthNatural Products and Biological ResearchComplementary and Alternative Medicine Studies

The Role of Nutraceuticals in Statin Intolerant Patients

Open access
Banach, Maciej, Patti, Angelo Maria, Giglio, Rosaria Vincenza, Cicero, Arrigo F.G., Atanasov, Atanas G., Bajraktari, Gani, Bruckert, Eric, Descamps, Olivier +29 more·2018·Journal of the American College of Cardiology
DOI 10.1016/j.jacc.2018.04.040
Open this paper in CoChat — free accountOpen PDF

Abstract

Statins are the most common drugs administered for patients with cardiovascular disease. However, due to statin-associated muscle symptoms, adherence to statin therapy is challenging in clinical practice. Certain nutraceuticals, such as red yeast rice, bergamot, berberine, artichoke, soluble fiber, and plant sterols and stanols alone or in combination with each other, as well as with ezetimibe, might be considered as an alternative or add-on therapy to statins, although there is still insufficient evidence available with respect to long-term safety and effectiveness on cardiovascular disease prevention and treatment. These nutraceuticals could exert significant lipid-lowering activity and might present multiple non-lipid-lowering actions, including improvement of endothelial dysfunction and arterial stiffness, as well as anti-inflammatory and antioxidative properties. The aim of this expert opinion paper is to provide the first attempt at recommendation on the management of statin intolerance through the use of nutraceuticals with particular attention on those with effective low-density lipoprotein cholesterol reduction.

AI snapshot

Written from the paper’s full text.

TL;DR

This International Lipid Expert Panel position paper reviews nutraceuticals as alternatives or add-ons for patients with statin intolerance/SAMS, focusing on agents with LDL-C-lowering evidence. It concludes that certain nutraceuticals may help achieve lipid targets and are generally well tolerated, but long-term cardiovascular outcome and safety data remain insufficient.

Key findings

  • Complete statin intolerance affects only 3% to 5% of patients, and for most (even 95%) with SAMS, statins can still be used with a step-by-step approach; nutraceuticals may be considered when statins are not tolerated or targets are not reached.
  • Reported LDL-C reductions vary by agent: RYR 15% to 25%, plant sterols/stanols 8% to 12%, soluble fiber 5% to 15%, bergamot 15% to 25%, berberine 15% to 20%, artichoke 5% to 15%; combinations include RYR + policosanols 15% to 21%, RYR + policosanols + berberine 20% to 25%, RYR + plant sterols 25% to 30%, and Armolipid Plus 15% to 30%.
  • In statin-intolerant patients, RYR 1,800 mg twice daily reduced LDL-C by 43 mg/dl at week 12 and 35 mg/dl at week 24, versus 11 mg/dl and 15 mg/dl with placebo; bergamot 1,500 mg/day in patients who stopped simvastatin reduced LDL-C by 25.0% and TG by 27.6% (p < 0.001 for all) without side effects.
  • Armolipid Plus studies reported target attainment: in one trial, 14 patients (28%) in the nutraceutical group reached therapeutic target at 3 months versus 0 in the ezetimibe group; in the ADHERENCE trial, LDS + Armolipid Plus reduced LDL-C by 26.8% and TC by 17.5% (p < 0.0001), with 70% reaching LDL-C <70 mg/dl.
  • Safety signals: RYR muscular symptoms occurred in 0% to 23.8% of RYR groups versus 0% to 36% of control groups, with no rhabdomyolysis or CK >10 times ULN; however, monacolin K is chemically identical to lovastatin, so statin-typical adverse effects might appear, and citrinin content/quality control are concerns.

Methods

  • Design: expert opinion/position paper from the International Lipid Expert Panel, intended to provide recommendations for nutraceutical therapy in statin-intolerant patients and to complement prior ILEP and EAS papers.
  • Data: review of available clinical studies, randomized controlled trials, meta-analyses, and selected perspective control studies on single nutraceuticals, combinations, and nutraceuticals with lipid-lowering drugs; detailed search strategy is in the Online Appendix.
  • Analysis: narrative synthesis with pre-defined grading of level of evidence (A–C) and class of recommendation (I–III), summarized in tables covering mechanisms, doses, LDL-C effects, other cardiovascular parameters, and safety.

Limitations

  • The paper states there is still insufficient evidence on long-term safety and effectiveness of nutraceuticals for cardiovascular disease prevention and treatment, and no long-term outcome studies confirm that nutraceuticals prevent CVD morbidity or mortality.
  • For most nutraceuticals in SAMS patients, only single studies have been published, except RYR (3 studies) and RYR combinations (5 studies); further studies with suitable patient numbers and longer follow-up are needed.
  • Evident from the text: recommendations are largely expert opinion and based on LDL-C-lowering data rather than hard outcome trials, with many recommendations graded Class IIb/Level C; product standardization, monacolin K variability, and potential statin-like effects of RYR are also noted concerns.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2018.04.040

Cites

Statistics

Nothing to recompute.

Claims the paper makes

0 of 111 cited sources checked · 0 supported · 0 flagged

  • Premisecitation

    Statins have significant non-lipid-lowering properties including anti-inflammatory, antithrombotic, antioxidant, and antiapoptotic activities.

    “They also have significant non-lipid-lowering properties, including anti-inflammatory, antithrombotic, antioxidant or antiapoptotic activities (3,6).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [3] Banach, 2009, Time for new indications for statins?, Med Sci Monit

      Not checked in the free run.

    • cites [6] Catapano, 2011, ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis source

      Not checked in the free run.

  • Premisecitation

    In a crossover trial of 21 hypercholesterolemic patients with statin resistance or intolerance, a soya drink lowered total cholesterol by 6.5% before and 7.4% after cow's milk supplementation.

    “The soya supplementation reduced plasma TC levels by 6.5% before cow's milk supplementation and by 7.4% after cow's milk supplementation.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [136] Sirtori, 1999, Double-blind study of the addition of high-protein soya milk v. cows' milk to the diet of patients with severe hypercholesterolaemia and resistance to or intolerance of statins, Br J Nutr source

      Not checked in the free run.

  • Premisecitation

    Combinations of nutraceuticals with different lipid-lowering activities and mechanisms, particularly when associated with an appropriate lifestyle, might have essential synergistic effects.

    “Combinations of nutraceuticals with different lipidlowering activities and mechanisms of action (19), particularly when associated with an appropriate lifestyle, might have essential synergistic effects (86-107) (Table 4)”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites 86-107

      Not checked in the free run.

  • Premisecitation

    In that study, group C receiving placebo did not show significant reductions in serum cholesterol.

    “Group C (placebo) did not show significant reductions in serum cholesterol”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [135] Mollace, 2011, Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies, Fitoterapia source

      Not checked in the free run.

  • Premisecitation

    Soy has demonstrated direct vascular effects, chiefly on flow-mediated dilation.

    “Direct vascular effects, mainly on FMD, have been demonstrated (19).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [19] Cicero, 2017, Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Arch Med Sci source

      Not checked in the free run.

  • May combine two claims. 43
  • Classified as probably not a substantial claim. 5
  • The quote only partly states this claim. 1

  • May combine two claims.

    Premisecitation

    For most patients with statin-associated muscle symptoms, even up to 95%, statins can still be used with a step-by-step approach, because complete statin intolerance affects only 3% to 5% of patients.

    “Moreover, for most (even 95%) of the patients with SAMS, it is still possible to use statins using a step-bystep approach, as complete statin intolerance affects only 3% to 5% patients (10)(11)(12).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [10] Rosenson, 2017, Optimizing cholesterol treatment in patients with muscle complaints, J Am Coll Cardiol source

      Not checked in the free run.

    • cites [11] Banach, 2016, Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement, Int J Cardiol source

      Not checked in the free run.

    • cites [12] Banach, 2016, Discussion around statin discontinuation in older adults and patients with wasting diseases, J Cachexia Sarcopenia Muscle source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Statin intolerance limits effective treatment of patients at risk of atherosclerotic cardiovascular disease and is the main cause of statin nonadherence and discontinuation.

    “In clinical practice, statin intolerance limits the effective treatment of patients at risk of atherosclerotic cardiovascular disease (CVD), and represents the main cause of statin nonadherence and discontinuation (11,12).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [11] Banach, 2016, Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement, Int J Cardiol source

      Not checked in the free run.

    • cites [12] Banach, 2016, Discussion around statin discontinuation in older adults and patients with wasting diseases, J Cachexia Sarcopenia Muscle source

      Not checked in the free run.

  • May combine two claims.

    Premisereasoning

    There is a potential safety concern if citrinin is present, and variation in monacolin K content within a given product seems important.

    “There is also a potential safety concern if citrinin is present; variation in the monacolin K content within a given product seems also to be important”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    In a study by Mollace et al., bergamot showed dose-dependent lipid-lowering action: in groups A and B, LDL-C decreased by 24.1% and 30.6%, triglycerides by 28.2% and 37.9%, and HDL-C increased by 22.3% and 40.1%, respectively, compared with baseline.

    “The results showed dose-dependent lipid-lowering action of bergamot (groups A and B LDL-C: À24.1% and À30.6%, TG: À28.2% and À37.9%, and HDL-C: þ22.3% and þ40.1%, respectively; p < 0.001 for all) compared with baseline.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [135] Mollace, 2011, Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies, Fitoterapia source

      Not checked in the free run.

  • May combine two claims.

    Interpretationnone given

    Clinical evidence supporting the use of nutraceuticals that improve lipid levels is largely variable, and for many nutraceuticals it is still very limited.

    “However, clinical evidence that supports the use of nutraceuticals that improve lipid levels is largely variable, and for many of them is still very limited.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Bergamot may potentially reduce overall cardiovascular risk, but effects on cardiovascular outcomes have not been demonstrated.

    “Bergamot may potentially reduce overall CV risk, but effects on CV outcomes have not been demonstrated (19).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [19] Cicero, 2017, Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Arch Med Sci source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In that trial, soya versus cow's milk changed total and LDL cholesterol by -6.1% and -7.0% at 2 weeks and -6.2% and -7.8% at 4 weeks, both significant.

    “Changes in total and LDL-C levels after soya versus cow's milk treatment were À6.1% and À7.0% after 2 weeks and À6.2% and À7.8% after 4 weeks, respectively (both p < 0.05) (136) (Table 9).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [136] Sirtori, 1999, Double-blind study of the addition of high-protein soya milk v. cows' milk to the diet of patients with severe hypercholesterolaemia and resistance to or intolerance of statins, Br J Nutr source

      Not checked in the free run.

  • May combine two claims.

    Interpretationnone given

    For most nutraceuticals presented, only single studies in patients with statin-associated muscle symptoms have been published, except red yeast rice, which has three available studies and another five for red yeast rice in combination with other nutraceuticals.

    “it needs to be emphasized that for most of the nutraceuticals presented in the following section, only single studies in SAMS patients have been published, with the exception of red yeast rice (RYR), which has 3 available studies and another 5 for RYR in combination with other nutraceuticals.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Use of high-intensity statins increases the risk of adverse effects and therefore worsens adherence.

    “The use of high-intensity statins increases the risk of adverse effects and, therefore, worsens adherence (11,124).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [11] Banach, 2016, Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement, Int J Cardiol source

      Not checked in the free run.

    • cites [124] Šimić, 2015, Adverse effects of statins—myths and reality, Curr Pharm Des source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationreasoning

    Data on the use of nutraceuticals in patients with statin-associated muscle symptoms or statin intolerance are even less, and for most nutraceuticals only an expert opinion recommendation might be given based only on confirmed LDL-C-lowering effectiveness and safety data.

    “The data on their use in patients with SAMS/ statin intolerance are even less, and for most of them only an expert opinion recommendation might be given based only on their confirmed LDL-C-lowering effectiveness and safety data.”
    Quote in the paperSubstantial claim
    • Rests on an assumption: LDL-C-lowering effectiveness and safety data are sufficient to recommend nutraceuticals for statin intolerant patients despite the lack of long-term outcome data.

  • May combine two claims.

    Premisecitation

    Nutraceuticals, either alone or in combination, when administered with statins seem to confer additional benefit on plasma lipid profiles, allowing statin doses to be reduced without diminishing total cholesterol and LDL-C reduction, and significantly limiting adverse effects.

    “Nutraceuticals, either alone or in combination, when administered with statins seem to confer additional benefit on plasma lipid profiles (Table 5), allowing the statin doses to be reduced (in case of statin intolerance) without diminishing the results in terms of total cholesterol (TC) and LDL-C reduction (109-121) and significantly limiting adverse effects (122).”
    Quote in the paperSubstantial claim0 of 10 sources checked
    • cites [109] Maki, 2013, A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial), Clin Ther source

      Not checked in the free run.

    • cites [110] Kim, 2011, Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability, Eur J Clin Nutr source

      Not checked in the free run.

    • cites [111] Yokoyama, 2007, Japan EPA lipid intervention study (JELIS) investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, Lancet source

      Not checked in the free run.

    • cites [112] 1999, Gruppo Italiano per lo Studio Della Sopravvivenza Nell'infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial, Lancet source

      Not checked in the free run.

    • cites [113] Agrawal, 2007, Effect of combining viscous fibre with lovastatin on serum lipids in normal human subjects, Int J Clin Pract source

      Not checked in the free run.

    • cites [114] Moreyra, 2005, Effect of combining psyllium fiber with simvastatin in lowering cholesterol, Arch Intern Med source

      Not checked in the free run.

    • cites [115] Ramos, 2011, The role of soluble fiber intake in patients under highly effective lipid-lowering therapy, Nutr J source

      Not checked in the free run.

    • cites [116] Malina, 2015, Additive effects of plant sterols supplementation in addition to different lipid-lowering regimens, J Clin Lipidol source

      Not checked in the free run.

    • cites [117] Gylling, 2002, LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects, Nutr Metab Cardiovasc Dis

      Not checked in the free run.

    • cites [118] Qureshi, 2001, Khan FA. Synergistic effect of tocotrienol-rich fraction (TRF 25) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans, J Nutr Biochem source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Nutraceuticals can help achieve lipid therapeutic goals and reduce cardiovascular residual risk, but data on cardiovascular residual risk are still limited.

    “Nutraceuticals can help achieve lipid therapeutic goals and reduce CV residual risk; however, data on the latter are still limited (19)”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [19] Cicero, 2017, Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Arch Med Sci source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Bergamot has a good efficacy and safety profile in dyslipidemic and other cardiometabolic patients without any adverse effects detected.

    “Bergamot has a good efficacy and safety profile in dyslipidemic and other cardiometabolic patients without any adverse effects detected.”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [19] Cicero, 2017, Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Arch Med Sci source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In that study, all participants with lifestyle changes had significant decreases in LDL-C and total cholesterol, and an increase in HDL-C for 1 year compared with baseline.

    “All participants with the lifestyle changes had significant decreases in LDL-C (À51 mg/dl [À1.3 mmol/l] vs. À42 mg/dl [À1.1 mmol/l]; p ¼ 0.006) and TC (p ¼ 0.003), and an increase in HDL-C for 1 year when compared with baseline (p < 0.001) (134).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [134] Becker, 2013, Phytosterols, red yeast rice, and lifestyle changes instead of statins: a randomized, double-blinded, placebo-controlled trial, Am Heart J source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing). May combine two claims.

    Premisecitation

    Phytosterolemia is a rare autosomal recessive sterol storage disease caused by mutations in ABCG5 or ABCG8, leading to impaired elimination of plant sterols and stanols.

    “This rare autosomal recessive sterol storage disease is caused by mutations in either the adenosine triphosphate (ATP)-binding cassette transporter genes ABCG5 or ABCG8, leading to impaired elimination of plant sterols and stanols.”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [132] Horenstein, 2013, The ABCG8 G574R variant, serum plant sterol levels, and cardiovascular disease risk in the Old Order Amish, Arterioscler Thromb Vasc Biol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Phytosterols have well-documented LDL-C lowering at Level A and absence of adverse signals according to the 2016 ESC/EAS lipid guidelines.

    “phytosterols have well-documented LDL-C lowering (Level of Recommendation: A) and the absence of adverse signals”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [7] Catapano, 2016, 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Atherosclerosis source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Increased accumulation of plant sterols and stanols in blood and tissues leads to moderate to high plasma cholesterol levels and increased risk of premature atherosclerosis.

    “The increased accumulation of plant sterols and stanols in the blood and tissues leads to moderate to high plasma cholesterol levels, and increased risk of premature atherosclerosis (133).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [133] Ajagbe, 2015, Plant sterols, stanols, and sitosterolemia, J AOAC Int

      Not checked in the free run.

  • May combine two claims.

    Interpretationreasoning

    Monacolin K is chemically identical to lovastatin, and therefore some adverse effects typical for statins might appear, despite available studies in patients with statin-associated muscle symptoms not confirming this.

    “However, it needs to be emphasized that monacolin K is chemically identical to lovastatin, and therefore, some adverse effects typical for statins might appear, despite the fact that available studies in SAMS patients have not confirmed this.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Clinical trials and meta-analyses have not shown any major safety concerns for phytosterols, nor is there evidence of direct vascular effects after their persistent use.

    “Clinical trials and meta-analyses have not shown any major safety concerns (131), nor is there any evidence of direct vascular effects after their persistent use (19).”
    Quote in the paperNot a substantial claim0 of 2 sources checked
    • cites [131] Miettinen, 1995, Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population, N Engl J Med source

      Not checked in the free run.

    • cites [19] Cicero, 2017, Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Arch Med Sci source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Red yeast rice has been used as an alternative to statin therapy in treating patients with mild to moderate hypercholesterolemia, particularly in those considered statin intolerant, and clinical studies suggest red yeast rice is well tolerated, safe, and effective for cardiovascular disease primary prevention.

    “RYR has been used as an alternative to statin therapy in treating patients with mild to moderate hypercholesterolemia, particularly in those considered to be statin intolerant, and clinical studies suggest that RYR is well tolerated, safe, and effective for CVD primary prevention (126-128).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [126] Becker, 2009, Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial, Ann Intern Med source

      Not checked in the free run.

    • cites [127] Karl, 2012, A multicentre study of nutritional drinks for cholesterol (evaluation effectiveness and tolerability), J Clin Lipidol source

      Not checked in the free run.

    • cites [128] Kasliwal, 2016, ESSENS dyslipidemia: a placental-controlled, randomized study of a nutritional supplement containing red yeast rice in subjects with newly diagnosed dyslipidemia, Nutrition source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    At 1 year, 58 (72.5%) of the combined therapy group and 14 (100%) of the nutraceutical group reached the therapeutic goal.

    “At 1-year follow-up, 58 patients (72.5%) of the combined therapy group (n ¼ 86) and 14 (100%) of the nutraceutical group reached the therapeutic goal (144).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [144] Marazzi, 2015, Usefulness of nutraceuticals (Armolipid Plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease, Am J Cardiol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    RYR has a safety profile similar to or better than low-dose statins.

    “It has been shown that the safety profile of RYR is similar to that of LDS or even less (175).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [175] Mazzanti, 2017, Adverse reactions to dietary supplements containing red yeast rice: assessment of cases from the Italian surveillance system, Br J Clin Pharmacol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Combined treatment with these drugs was as effective as moderate-dose statins, lowering LDL-C by 37% and TC by 23%.

    “Combined treatment with these drugs was as effective as statins in moderate doses (LDL-C À37%, TC À23%) (147).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [147] Pisciotta, 2012, Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment, Lipids Health Dis source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In 228 hypercholesterolemic subjects with statin intolerance or refusal, a nutraceutical pill (berberine 500 mg, policosanol 10 mg, RYR 200 mg) reduced LDL-C more than ezetimibe (-31.7% vs -25.4%) and was better tolerated; LDL-C <3.36 mmol/l occurred in 28.9% vs 11.8%.

    “In hypercholesterolemic subjects, the nutraceutical pill compared with ezetimibe resulted in more effective reduction of LDL-C (À31.7 vs. À25.4%;p < 0.001) and was better tolerated; LDL-C levels below 3.36 mmol/l (#130 mg/dl) were observed in 28.9% of subjects treated with the nutraceutical pill and 11.8% of those treated with ezetimibe (p < 0.007) (147).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [147] Pisciotta, 2012, Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment, Lipids Health Dis source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Armolipid Plus lowers TC by 11-21% and LDL-C by 15-31%, equivalent to low-dose statin changes.

    “Armolipid Plus induces reductions in TC (11% to 21%; p ¼ 0.001) and LDL-C (15% to 31%; p ¼ 0.001) levels, which is equivalent to changes associated with LDS.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [145] Marazzi, 2017, Comparison of low-dose statin versus low-dose statin + Armolipid Plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE Trial), Am J Cardiol source

      Not checked in the free run.

    • cites [146] Barrios, 2017, A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence, Atheroscler Suppl source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Nutraceuticals can be useful in statin intolerance if they improve low-grade systemic inflammation and lipid abnormalities, with LDL-C reductions usually below 10-20%.

    “With this background, nutraceuticals can be very useful in case of statin intolerance if they improve the control of low-grade systemic inflammation (157) and lipid abnormalities (LDL-C reduction usually <10% to 20%).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [157] Jenkins, 2003, Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein, JAMA source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In the ADHERENCE trial, after 3 months the LDS plus Armolipid Plus group had significant LDL-C and TC reductions and 70% reached LDL-C <70 mg/dl, while the LDS group did not.

    “After 3 months, patients in the LDS þ Armolipid Plus (n ¼ 50) group had a substantial reduction in LDL-C (À26.8%;p < 0.0001) and TC (À17.5;p < 0.0001), and 70% of patients in this group reached the treatment target (LDL-C <70 mg/dl), whereas patients in the LDS group did not (145).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [145] Marazzi, 2017, Comparison of low-dose statin versus low-dose statin + Armolipid Plus in high-intensity statin-intolerant patients with a previous coronary event and percutaneous coronary intervention (ADHERENCE Trial), Am J Cardiol source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S4 (based).

    Interpretationnone given

    Statin discontinuation due to exaggerated toxicity concerns is a significant and growing worldwide problem.

    “Statin discontinuation due to exaggerated toxicityrelated concerns is a significant problem worldwide and appears to be growing.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    PUFA has demonstrated direct vascular effects on FMD and PWV and a role in reducing cardiovascular outcomes.

    “Direct vascular effects (FMD, PWV) have been demonstrated, as well as their role in reduction of CV outcomes (19).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [19] Cicero, 2017, Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel, Arch Med Sci source

      Not checked in the free run.

  • May combine two claims. The quote only partly states this claim.

    Premisecitation

    In 45 patients with type 2 diabetes, hypercholesterolemia, and statin intolerance, berberine/silymarin with statins improved LDL-C by 15% and 28% at 6 and 12 months, and with ezetimibe by 20% and 33%.

    “The intake of berberine/ silymarin with statins led to an improvement of lipid parameters (LDL-C À15% and À28%, respectively, after 6 and 12 months; p < 0.01) and also when added to ezetimibe (LDL-C À20% and À33%, respectively, after 6 and 12 months; p < 0.01).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [148] Di Pierro, 2015, Clinical role of a fixed combination of standardized Berberis aristata and Silybum marianum extracts in diabetic and hypercholesterolemic patients intolerant to statins, Diabetes Metab Syndr Obes source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Because curcumin also modifies lipids, it may be added to SAMS therapy to achieve LDL-C reduction with a lower statin dose.

    “Since curcumin also has lipid-modifying properties, it may serve as additive to therapy in SAMS patients, enabling effective LDL-C reduction with decreased statin dose (173).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [173] Sahebkar, 2017, Curcumin: an effective adjunct in patients with statin-associated muscle symptoms?, J Cachexia Sarcopenia Muscle source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    HMB, beta-alanine, and carnosine are known to improve muscle mass, function, hypertrophy, lean mass, aerobic performance, exercise capacity, and muscle protein synthesis, and to reduce muscle damage, protein breakdown, and fatigue.

    “Besides the nutraceuticals with LDL-lowering properties, it is worth mentioning those, such as b-hydroxy b-methylbutyric acid, b-alanine, and carnosine, that are known to improve muscle mass, muscle function, hypertrophy, lean body mass, aerobic performance and exercise capacity, and muscle protein synthesis, as well as to decrease muscle damage and muscle protein breakdown and fatigue (178,179).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites [178] Muntean, 2017, Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms?, Drug Discov Today source

      Not checked in the free run.

    • cites [179] Wilson, 2014, The effects of 12 weeks of beta-hydroxy-beta-methylbutyrate free acid supplementation on muscle mass, strength, and power in resistance-trained individuals: a randomized, double-blind, placebo-controlled study, Eur J Appl Physiol source

      Not checked in the free run.

  • May combine two claims.

    Interpretationcitation

    Some nutraceuticals can enhance or potentially replace statin action.

    “some nutraceuticals are then able to enhance (126,127,135-137,145-147) or potentially replace the action of statins (63-66,50-52,58,168,169).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [126] Becker, 2009, Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial, Ann Intern Med source

      Not checked in the free run.

    • cites [127] Karl, 2012, A multicentre study of nutritional drinks for cholesterol (evaluation effectiveness and tolerability), J Clin Lipidol source

      Not checked in the free run.

    • cites [135] Mollace, 2011, Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies, Fitoterapia source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Armolipid Plus improves vascular stiffness, an independent predictor of cardiovascular events.

    “Moreover, Armolipid Plus offers the additional benefit of improving vascular stiffness, which is an independent predictor of CV events (146).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [146] Barrios, 2017, A nutraceutical approach (Armolipid Plus) to reduce total and LDL cholesterol in individuals with mild to moderate dyslipidemia: Review of the clinical evidence, Atheroscler Suppl source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Statin therapy lowers plasma cholesterol and high-sensitivity C-reactive protein, and this is directly associated with improved cardiovascular risk.

    “Statin therapy can reduce plasma cholesterol (3,5) and high-sensitivity C-reactive protein levels, and this is directly associated with a significant improvement in CV risk (1,2,6,149,150).”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites [1] Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol source

      Not checked in the free run.

    • cites [2] Banach, 2017, PoLA/CFPiP/PCS guidelines for the management of dyslipidaemias for family physicians 2016, Arch Med Sci source

      Not checked in the free run.

    • cites [6] Catapano, 2011, ESC/EAS guidelines for the management of dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Atherosclerosis source

      Not checked in the free run.

  • May combine two claims.

    Interpretationnone given

    Despite insufficient data, nutraceutical therapy appears very safe and well tolerated.

    “Equally important, despite still insufficient data, is that therapy with nutraceuticals seems to be very safe and well tolerated.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Because PUFA results for cardiovascular outcomes conflict, some dyslipidemia guidelines advise against PUFA to reduce CVD events while others do not.

    “However, due to conflicting results on the role of PUFA in reduction of CV outcomes (140,141), some dyslipidemia guidelines do not recommend using PUFA to reduce CVD events (142), in contrast to other guidelines (2,7).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [140] Rizos, 2012, Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis, JAMA source

      Not checked in the free run.

    • cites [141] Aung, 2018, Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77 917 individuals, JAMA Cardiol source

      Not checked in the free run.

    • cites [142] Anderson, 2016, 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult, Can J Cardiol source

      Not checked in the free run.

  • Classified as probably not a substantial claim. May combine two claims.

    Interpretationreasoning

    Nutraceuticals can supplement statin and nonstatin lipid-lowering therapy but cannot replace them.

    “It is, however, important to emphasize once again that nutraceuticals can complement lipid-lowering therapy with statin and nonstatin agents, but they cannot replace them.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Lifestyle improvements usually lower LDL-C by 5-15%, and maintaining this long-term may meaningfully reduce CVD risk.

    “In fact, LDL-C reductions with lifestyle improvements are most often in the range of 5% to 15%, an amount that, if maintained over a long period, may result in meaningful CVD risk reduction (158-160).”
    Quote in the paperNot a substantial claim0 of 3 sources checked
    • cites [158] 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation source

      Not checked in the free run.

    • cites [159] Appel, 2005, Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: results of the OmniHeart randomized trial, JAMA source

      Not checked in the free run.

    • cites [160] Brown, 2006, Lowering LDL—not only how low, but how long?, Science source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Some nutraceuticals have good safety, high LDL-C and other lipid efficacy, and vascular benefits but have not been studied in SAMS patients.

    “There are also some nutraceuticals with a good safety profile, high efficacy on LDL-C as well as on other lipid parameters, and beneficial effects on a vascular level; however, so far, they have not been investigated in patients with SAMS (Table 3).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Table 3

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    In both groups, LDL-C, TC, and TG fell significantly from baseline and HDL-C rose significantly.

    “values progressively and significantly decreased from baseline throughout treatment (p < 0.001 for all), whereas HDL-C (40 Æ 7 mg/dl [1.03 Æ 0.18 mmol/l] vs. 41 Æ 8 mg/dl [1.06 Æ 0.21 mmol/l]) values progressively and significantly increased in both groups (p < 0.001) (144).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [144] Marazzi, 2015, Usefulness of nutraceuticals (Armolipid Plus) versus ezetimibe and combination in statin-intolerant patients with dyslipidemia with coronary heart disease, Am J Cardiol source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    Becker et al. showed RYR significantly reduced LDL-C and TC versus placebo without increasing myalgia in 62 dyslipidemic statin-intolerant patients.

    “Becker et al. (126) showed that the use of RYR significantly reduced LDL-C and TC levels compared with placebo without increasing the incidence of myalgia in 62 dyslipidemic patients who could not tolerate statin therapy (126).”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [126] Becker, 2009, Red yeast rice for dyslipidemia in statin-intolerant patients: a randomized trial, Ann Intern Med source

      Not checked in the free run.

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    The EAS consensus on SAMS recommends plant sterol diet, soy proteins, viscous fibers, and nuts alone or with a statin.

    “The EAS consensus paper on SAMS recommends an approach with a plant sterol diet, soy proteins, viscous fibers, and nuts alone or in combination with a statin in patients with SAMS (21)”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites [21] Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management, Eur Heart J source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    After 4 weeks, RYR reduced LDL-C by 1.02 mmol/l (39 mg/dl) versus placebo, and its LDL effect did not differ from statin therapy.

    “After 4 weeks, RYR reduced LDL-C by 1.02 mmol/l (39 mg/dl; p < 0.0001) compared with placebo, and the effect of RYR on LDL was not different from statin therapy (0.03 mmol/l [1.2 mg/dl]; p ¼ 0.89) in statin-”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [80] Gerards, 2015, Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain—a systematic review and meta-analysis, Atherosclerosis source

      Not checked in the free run.

  • May combine two claims.

    Premisecitation

    ESC/EAS guidelines state plant sterols/stanols can be considered for high cholesterol with low-to-intermediate CV risk not qualifying for drugs, with pharmacotherapy in high/very-high risk statin-intolerant or not-at-target patients, and in adults and children over 6 with familial hypercholesterolemia.

    “The current ESC/EAS lipid guidelines state that, based on the reduction of LDL-C and the absence of adverse events, the use of plant sterols/stanols can be considered: 1) in subjects with high cholesterol levels with low to intermediate CV risk who do not qualify for pharmacological treatment; 2) in combination with pharmacotherapy in high-risk or very-high-risk patients who have been statin-intol”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites [7] Catapano, 2016, 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS), Atherosclerosis source

      Not checked in the free run.

45 of 45

  • The paper relies on this without support.

    There are only three statin-associated adverse effects with confirmed causality: myalgia/myopathy, temporary elevation of alanine aminotransferase, and new-onset diabetes.

    “It is, however, important to emphasize that there are only 3 statin-associated adverse effects with the confirmed causality: myalgia/myopathy, temporary elevation of alanine aminotransferase, and new-onset diabetes.”

  • The paper relies on this without support.

    LDL-C-lowering effectiveness and safety data are sufficient to recommend nutraceuticals for statin intolerant patients despite the lack of long-term outcome data.

    “The data on their use in patients with SAMS/ statin intolerance are even less, and for most of them only an expert opinion recommendation might be given based only on their confirmed LDL-C-lowering effectiveness and safety data.”

  • The paper relies on this without support.

    PUFA mainly lowers triglycerides and has relatively little effect on LDL-C.

    “Taking into account that PUFA mainly works on TG levels with a relatively small effect on LDL-C, they should be mainly considered for statin-intolerant patients with obesity, diabetes (insulin resistance), or metabolic syndrome in whom elevated LDL-C is accompanied by high levels of TGs (atherogenic dyslipidemia).”

  • The paper relies on this without support.

    Some fish oils may contain mercury, dioxins, other contaminants, and saturated fats.

    “Finally, we recommend using PUFA from sources of confirmed quality (e.g., pure algal-based long-chain n-3 fatty acids), because of their lack of mercury, dioxins, and other contaminants-requiring distillation techniques to remove potential toxins-as well as saturated fats, which might be present in some fish oils (Table 10).”

  • The paper relies on this without support.

    Red yeast rice at 1,200-4,800 mg/day (3-10 mg monacolin K) lowers LDL-C by 15-25%.

    “À15% to À25%”

  • The paper relies on this without support.

    Bergamot at 500-1,500 mg/day lowers LDL-C by 15-25%.

    “500-1,500 mg”
    “À15% to À25%”

  • The paper relies on this without support.

    Bergamot has no safety concerns.

    “No safety concerns”
7 of 7

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The lipid-lowering mechanisms of berberine might be enhancing hepatic uptake of LDL particles by inhibiting PCSK9, decreasing intestinal cholesterol absorption, increasing fecal cholesterol excretion, and enhancing hepatic cholesterol turnover.

    “The mechanisms might be due to berberine enhancing the hepatic uptake of LDL particles by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), decreasing intestinal cholesterol absorption, increasing fecal cholesterol excretion, and enhancing hepatic cholesterol turnover.(5)”

    From Overall and sex-specific effect of berberine for dyslipidemia: systematic review and meta-analysis of placebo-controlled trials (2022) · cites this paper as [5]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Combined-therapy success rate uses the wrong denominator

    Major

    The reported 58 patients out of 86 is 67.4%, not 72.5%. The stated 72.5% would correspond to 58 out of 80 patients.

    Reported 72.5 · recomputed 67.44186

  • Claim of no long-term mortality-outcome studies conflicts with an outcome reported for XZK

    Major

    The paper says no long-term outcome studies confirm that nutraceuticals prevent cardiovascular mortality, yet it reports significantly lower cardiovascular and total mortality in patients assigned to the red yeast rice extract XZK. It also describes the XZK follow-up as averaging 4.5 years.

2 of 2

The citation lists haven’t been fetched yet

References 190 · Cited by 272

Authors
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., Fras, Z., von Haehling, S., Katsiki, N., Langlois, M., Latkovskis, G., Mancini, G. B. J., Mikhailidis, D. P., Mitchenko, O., Moriarty, P. M., Muntner, P., Nikolic, D., Panagiotakos, D. B., Paragh, G., Paulweber, B., Pella, D., Pitsavos, C., Reiner, Ž., Rosano, G. M. C., Rosenson, R. S., Rysz, J., Sahebkar, A., Serban, M.-C., Vinereanu, D., Vrablík, M., Watts, G. F., Wong, N. D., & Rizzo, M.
Affiliations
  • Medical University of Lodz (PL)
  • University of Palermo (IT)
  • University of Bologna (IT)
  • University of Vienna (AT)
  • University Clinical Center of Kosovo (XK)
  • Cliniques Universitaires Saint-Luc (BE)
  • University of Belgrade (RS)
  • University of Ljubljana (SI)
  • Aristotle University of Thessaloniki (GR)
  • AZ Sint-Jan (BE)
  • University of Latvia (LV)
  • University of British Columbia (CA)
  • The Royal Free Hospital (GB)
  • University of Kansas Medical Center (US)
  • University of Alabama at Birmingham (US)
  • Harokopio University of Athens (GR)
  • Paracelsus Medical University (AT)
  • University of Pavol Jozef Šafárik (SK)
  • National and Kapodistrian University of Athens (GR)
  • University Hospital Centre Zagreb (HR)
  • St George's Hospital (GB)
  • Icahn School of Medicine at Mount Sinai (US)
  • Mashhad University of Medical Sciences (IR)
  • The University of Western Australia (AU)
  • University of California, Irvine (US)
Corresponding author
Banach, Maciej
ORCID
Venue
Journal of the American College of Cardiology
Publisher
Elsevier BV
Published
2018-07
Volume
72
Issue
1
Pages
96-118
ISSN
0735-1097 (ISSN-L)
DOI
10.1016/j.jacc.2018.04.040
OpenAlex
W2810309731
Semantic Scholar
12e82348d45e39fa6c65e0d1a80459be00548e67
Cited by
272
References
190
Citations by year
2026: 11 · 2025: 15 · 2024: 18 · 2023: 29 · 2022: 43 · 2021: 46 · 2020: 51 · 2019: 45 · 2018: 12
FWCI
8.55
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of the American College of Cardiology (publishedVersion)
  • PubMed (publishedVersion)
  • HAL (submittedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
  • University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion, other-oa)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion, other-oa)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, other-oa)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Natural Products and Biological Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
Keywords
nutraceuticals, statin intolerance, statin-associated muscle symptoms, red yeast rice, bergamot, berberine, artichoke, soluble dietary fiber, ezetimibe, hypolipidemic activity, LDL cholesterol lowering, endothelial dysfunction, arterial stiffness, anti-inflammatory activity, antioxidant activity, cardiovascular disease prevention, statin adherence
MeSH terms
Clinical Studies as Topic, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dietary Supplements, Dyslipidemias

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-08.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-08.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review